肝细胞癌患者血清VEGF和NO含量测定及其临床意义

Measurement of serum VEGF and NO in patients with hepatocellular carcinoma and its clinical significance

目的研究血管内皮生长因子(VEGF)和一氧化氮(NO)在肝细胞癌患者血清中的表达水平,并探讨其临床意义。方法分别采用酶联免疫吸附试验(ELISA)和分光光度法检测60例肝细胞癌、48例良性肝病患者和32名健康人血清中VEGF和NO的含量。结果良性肝病患者血清中VEGF和NO含量与健康人比较,差异均无统计学意义(P>0.05);而肝细胞癌患者血清VEGF和NO含量较良性肝病患者和健康人明显增高(P<0.01),且随着肝细胞癌门静脉癌栓形成、肿瘤体积增大以及临床分期愈晚而显著增高(P<0.01)。血清VEGF与NO含量呈明显正相关(r=0.836,P<0.01)。结论VEGF和NO可能与肝细胞癌的发生、发展密切相关,治疗前检测血清VEGF和NO表达水平可以作为判断肝细胞癌侵袭、生长及临床分期的有价值指标。

Objective To study the clinical significance of the serum levels of vasular endothelial growth factor （VEGF） and nitric oxide （NO） in patients with hepatocellular carcinoma. Methods The serum level of VEGF was measured by enzyme-linked immunosorbent assay （ ELISA ） and that of NO was detected by spectrophotometry in 60 patients with hepatocellular carcinoma, 48 patients with benign liver deseases and 32 healthy subjects. Results The serum levels of VEGF and NO in patients with benign liver deseases showed no significant difference from those in healthy subjects （ P 〉 0. 05 ）. The serum levels of VEGF and NO in patients with hepatocellular carcinoma were significantly higher than those in patients with benign liver deseases and healthy subjects （P 〈 0.01 ）. There was a positive correlation between serum VEGF, NO levels and tumor with portal vein invasion, tumor size and clinical stage （P 〈0. 01 ）. There was also a positive correlation between serum VEGF level and serum NO level （r = 0. 836 ,P 〈 0.01 ）. Conclusions VEGF and NO may be related to the onset and progression of hepatocellular carcinoma. The pretherapeutic serum levels of VEGF and NO in patients with hepatocellular carcinoma may be valuable indexes for judgement of invasion and clinical stage.